PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) Director Stephanie Okey sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $54.00, for a total transaction of $270,000.00. Following the completion of the sale, the director now owns 8,867 shares in the company, valued at approximately $478,818. This trade represents a 36.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
PTC Therapeutics Price Performance
NASDAQ PTCT opened at $57.17 on Tuesday. The company has a 50 day simple moving average of $48.83 and a 200-day simple moving average of $43.78. The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of -9.62 and a beta of 0.66. PTC Therapeutics, Inc. has a 52-week low of $24.00 and a 52-week high of $58.66.
Institutional Trading of PTC Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Vontobel Holding Ltd. acquired a new position in PTC Therapeutics in the fourth quarter worth approximately $521,000. Charles Schwab Investment Management Inc. increased its holdings in PTC Therapeutics by 7.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 706,730 shares of the biopharmaceutical company’s stock worth $26,220,000 after buying an additional 47,902 shares during the last quarter. Two Sigma Advisers LP increased its holdings in PTC Therapeutics by 10.3% in the third quarter. Two Sigma Advisers LP now owns 429,842 shares of the biopharmaceutical company’s stock worth $15,947,000 after buying an additional 40,300 shares during the last quarter. Intech Investment Management LLC acquired a new position in PTC Therapeutics in the third quarter worth approximately $698,000. Finally, Quest Partners LLC increased its holdings in PTC Therapeutics by 433.9% in the third quarter. Quest Partners LLC now owns 22,359 shares of the biopharmaceutical company’s stock worth $830,000 after buying an additional 18,171 shares during the last quarter.
Analyst Ratings Changes
Read Our Latest Stock Analysis on PTCT
PTC Therapeutics Company Profile
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Recommended Stories
- Five stocks we like better than PTC Therapeutics
- How to Evaluate a Stock Before Buying
- Can TikTok Stock Picks Really Make You Rich?
- Technology Stocks Explained: Here’s What to Know About Tech
- The “Quality” Rotation: Back to Basics Investing
- Best Stocks Under $5.00
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.